UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 8, 2006
BOSTON SCIENTIFIC CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware |
|
001-11083 |
|
04-2695240 |
|
(State or Other Jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer Identification |
|
|
|
|
|
|
|
One Boston Scientific Place, Natick, Massachusetts |
|
01760-1537 |
||
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: (508) 650-8000
Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
o Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
Item 8.01. Other Events
On January 8, 2006, Boston Scientific Corporation (“Boston Scientific”) issued a press release announcing its submission of a definitive offer to acquire Guidant Corporation (“Guidant”). The offer was communicated on January 8, 2006 in a letter from Pete Nicholas, Chairman of Boston Scientific, and Jim Tobin, President and Chief Executive Officer of Boston Scientific, to James M. Cornelius, Chairman of Guidant. The press release announcing the offer, including the full text of the offer letter delivered to Mr. Cornelius, is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
Also on January 8, 2006, Boston Scientific issued a press release announcing that it had entered into a binding definitive agreement with Abbott to sell Guidant’s vascular intervention and endovascular businesses. The press release announcing the agreement is attached as Exhibit 99.2 to this Current Report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
99.1 Press release, dated January 8, 2006
99.2 Press release, dated January 8, 2006
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BOSTON SCIENTIFIC CORPORATION |
||
|
|
|
|
|
|
|
By: |
/s/ Lawrence J. Knopf |
|
|
|
Name: |
Lawrence J. Knopf |
|
|
|
Title: |
Vice President and Assistant General Counsel |
|
Dated: January 10, 2006
2